What are the characteristics of TME PHARMA stock?

TME PHARMA is a company operating in the Biotechnologies sector. The stock is listed on Euronext Paris under ISIN NL0015000YE1.

What is the recent price evolution of TME PHARMA stock?

Since last close: 2.83 %. Over one week: -14.31 %. Over one year: -0.96 %.

TME Pharma: Advanced Negotiations for NOX-A12 Licensing Agreement

The biotechnology company provided an update on its activities on August 24, 2026, clarifying that it is entering the final evaluation phase of advanced negotiations with two potential partners for a licensing agreement covering its main oncology asset.

The group is now approaching the partner selection phase to ensure advanced-stage development and commercialization of NOX-A12.

Published on Aug 24, 2026 at 10:47

TME PHARMA

0.10 € +2.83 %

Add us as a preferred source on Google

Licensing Agreement to Continue NOX-A12 Development

NOX-E36 Redirected Toward Licensing, GRDC Project Abandoned

Free · Every morning

Technical market signals, before the opening bell.

Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.

✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

Indicative data. No investment advice. Unsubscribe at any time.

Context

Period

Period: FY2025

Key reported figures

Net income: -3,3 millions d'euros

Risks mentioned

Les capitaux propres au 31 décembre 2025 sont désormais négatifs de 1,6 million d'euros.
L'absence de chiffre d'affaires génère des incertitudes financières.

Opportunities identified

TME Pharma se concentre sur la conclusion d'accords de licence pour NOX-A12 et NOX-E36.

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Licensing Agreement to Continue NOX-A12 Development

NOX-E36 Redirected Toward Licensing, GRDC Project Abandoned

Context

Also read